Q&A: The importance of patient selection for immunotherapy drugs

PD-L1 inhibitors have changed the paradigm for treatment of many cancers. For certain patients — like those with metastasized malignant melanoma — these immunotherapy drugs have offered the potential for a cure. Yet, across the cancer treatment landscape today, just 30% of patients who receive PD-L1 inhibitors benefit from them. Dr. Andrew Hertler, Evolent’s chief medical officer emeritus and senior advisor,  speaks with Urban Health Today about the importance of identifying those patients who are highly unlikely to live longer with these drugs.

Read article.